MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
AXSM - Axsome Therapeutics Inc
$67.36
-1.02(-1.49%)9:00:00 PM 2/26/2021
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the phase III clinical trial for the treatment resistant depression and depressive disorders; and phase II/III clinical trials in agitation associated with Alzheimer's disease, as well as completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07, which is in phase III clinical trial for the treatment of migraine; AXS-09 that has completed phase II clinical trial for the treatment of various CNS disorders; AXS-12, which has completed phase II clinical trial for the treatment of in narcolepsy; and AXS-14, an investigational medicine that is in phase III for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was founded in 2012 and is based in New York, New York.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
Peers

Related Peers

Stock news

    02/19/2021AXSM
    Axsome Therapeutics to Present at Upcoming Investor Conferences

    NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, will participate in two upcoming investor conferences: 10th Annual SVB Leerink Global Healthcare Conference, on February 24, 2021 at 2:20 PM Eastern Time. Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a virtual fireside chat.Cowen 41st Annual Health Care Conference, ...

    02/16/2021AXSM
    Axsome Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on March 1, 2021

    Axsome to host conference call and webcast on Monday, March 1, 2021 at 8:00 AM Eastern Time NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for fiscal year 2020 on Monday, March 1, 2021 before the opening of the U.S. financial markets. Axsome’s management team will host a conference cal...

    02/10/2021AXSM
    Forget Bitcoin: This Biotech Stock Is a Better Buy in 2021

    Bitcoin and other cryptocurrencies are all the rage these days, and many investors are thinking of jumping on the bandwagon. The value of fiat currency is, roughly speaking, determined by the government. If Bitcoin ends up replacing this kind of money in the future, those who got on early would be sitting pretty.

    01/27/2021AXSM
    Is It Too Late to Get In On This Millionaire-Making Stock?

    This is an amazing biotech with multiple drugs in pivotal trials. The U.S. Food and Drug Administration (FDA) has named this drug a breakthrough therapy in two indications: major depressive disorder and agitation caused by Alzheimer's Disease. Axsome is prepping its new drug application (NDA) right now for AXS-05 to treat major depressive disorder.

    01/7/2021AXSM
    Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock Options

    Investors need to pay close attention to Axsome Therapeutics (AXSM) stock based on the movements in the options market lately.

    01/4/2021AXSM
    Axsome's (AXSM) Migraine Drug Shows Long-Term Safety in Study

    Axsome (AXSM) posts favorable data from the long-term phase III study evaluating AXS-07 for acute treatment of migraine. The company also begins a second phase III study on AXS-05 for AD agitation.

    12/31/2020AXSM
    Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation

    ACCORD is the second pivotal trial of AXS-05 in Alzheimer’s disease agitationNo treatments are currently approved for Alzheimer’s disease agitationNEW YORK, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced the initiation of the ACCORD (Assessing Clinical Outcomes in Alzheimer’s Disease Agitation) study, a Phase 3, randomized, double-blind, plac...

    12/31/2020AXSM
    Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine

    Over 21,000 migraine attacks treated with AXS-07Achieved migraine pain relief in approximately 70% of patients, and pain freedom in approximately 40% of patients, at 2 hoursAchieved durable relief, with approximately 85% of patients free from rescue medication use over 48 hoursLong-term safety profile consistent with previously completed controlled trialsNDA on track for submission in 1Q 2021NEW YORK, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical...